IMMB OTC
Immunotech Laboratories, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +100.0%
1Y: +100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.1M
52W Range0.000099999997-0.0002
Volume244,208
Avg Volume4,073
Beta-5.14
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJennifer L. Bath
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2001-12-27
Websiteimmunotechlab.com
120 West Pomona Avenue
Monrovia, CA 91016
US
Monrovia, CA 91016
US
+1 954 636 1245
About Immunotech Laboratories, Inc.
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Latest News
No recent news
Recent Insider Trades
No insider trades found